Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

BRAF

12 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology

Upfront Comprehensive Genomic Profiling in Advanced Biliary Tract Cancer: Real-World Implementation and Clinical Outcomes

Hussung S, Roth M, Akhoundova D, et al.

Cancer medicine

This real-world study evaluated the implementation of upfront comprehensive genomic profiling (CGP) in 80 patients with advanced biliary tract cancer (BTC). Clinically actionable alterations were detected in 52.5% of cases—predominantly in IDH1, FGFR2, ERBB2, KRAS G12C, and BRAF—with anatomical enrichment of FGFR2 and IDH1 in intrahepatic cholangiocarcinoma. Matched targeted therapies were administered to 11 of the 42 actionable patients, yielding a significantly longer treatment duration compared with the preceding systemic line (p = 0.0391) and enabling secondary surgical resection in two patients. These findings confirm the clinical feasibility and value of upfront CGP in BTC while emphasizing the critical need to bridge the gap between biomarker identification and drug access.

Clinical · Molecular biology

Integrated longitudinal analysis of ctDNA, radiologic response, and tumor volume reveals spatial and temporal heterogeneity in advanced melanoma

Heidrich I, Streckenbach A, Rautmann C, et al.

Journal of translational medicine

This study longitudinally analyzed circulating tumor DNA (ctDNA) in 42 patients with advanced melanoma treated with immune checkpoint inhibitors. ctDNA levels significantly correlated with radiological response according to RECIST 1.1 and total tumor volume, especially when measurements were temporally aligned. Although the discriminative performance for identifying progression was moderate, higher ctDNA thresholds demonstrated better specificity. The study also revealed marked heterogeneity in ctDNA shedding across metastatic sites, highlighting its potential as a complementary biomarker for disease monitoring.

Clinical · Molecular biology

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

Cowzer D, Walch H, Atri P, et al.

Clinical cancer research

This study analyzed a cohort of 1,254 patients with biliary tract cancer to assess the utility of targeted NGS molecular profiling. It revealed that 59% of patients harbored at least one OncoKB alteration, and 32.2% had level 1/2 alterations, with varying frequencies across tumor locations. Targeted therapies were associated with improved progression-free survival but not overall survival. The study also identified co-occurring alterations and acquired resistance mechanisms, such as ERBB2 loss or alterations in the RAS, MEK, MET, MYC, and CDKN2A pathways. These findings highlight genomic heterogeneity and the importance of precision medicine in informing future drug development efforts.

Clinical · Molecular biology

Exploring the Role of TERT Promoter Mutations in Advanced Melanoma Treated With BRAF/MEK Inhibitors or Immune Checkpoint Inhibitors

Marchese PV, Zannini I, DE Biase D, et al.

Anticancer research

This retrospective single-center study investigated the role of TERT promoter mutations as a biomarker to guide treatment in advanced melanoma, particularly in BRAF V600 mutant patients. TERT mutations were detected in 73% of 159 patients and frequently co-occurred with BRAF V600 mutations. While TERT status was not an independent prognostic factor, exploratory analyses suggested a potential interaction with treatment type. Patients with BRAF/TERT co-mutations showed longer overall survival when treated with immune checkpoint inhibitors, whereas the opposite trend was observed for TERT wild-type patients receiving BRAF/MEK inhibitors. These preliminary findings warrant further validation in prospective studies.

Clinical · Molecular biology

Utility of RNA Sequencing and Immunohistochemistry for NTRK Fusion in Thyroid Carcinoma

Toda S, Kasajima R, Okubo Y, et al.

Anticancer research

This study evaluated the utility of RNA sequencing and immunohistochemistry (IHC) for detecting NTRK fusions in thyroid carcinoma, particularly those potentially missed by gene panel testing. Two patient groups were analyzed: advanced thyroid cancer cases undergoing panel testing and surgical papillary thyroid carcinoma cases screened by IHC. Results indicated that a gene panel test missed one SQSTM1-NTRK3 fusion, while pan-TRK IHC showed variable sensitivity depending on the fusion type. The study concludes that active screening for NTRK fusions is desirable, especially in patients without MAPK pathway abnormalities or with positive pan-TRK staining.

Clinical · Molecular biology

Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption

Yoshikawa Y, Kubota H, Matsumoto S, et al.

Nature communications

This study focuses on developing novel inhibitors targeting the RAS/RAF pathway, a significant challenge in oncology given the frequency of RAS mutations and acquired resistance to existing treatments. Researchers identified small molecules that covalently bind to a distinct site within the RAS-binding domain of RAF, leading to allosteric disruption of its conformation. This mechanism prevents RAS/RAF interaction and downstream signaling. These compounds demonstrated preclinical antitumor efficacy against various cancers with KRAS, NRAS, and HRAS mutations, as well as wild-type RAS-driven cancers. They also suppressed tumor growth in BRAFV600E melanoma with acquired BRAF inhibitor resistance by preventing RAS signal reactivation.

Clinical · Molecular biology · Bioinfo & AI

MET-amplified gastric cancers exhibit co-amplifications of BRAF, CDK6, and EGFR

Lüschen S, Ebert U, Behrens HM, et al.

The journal of pathology. Clinical research

This study investigated additional genetic alterations in MET-amplified gastric cancers (GCs), which are associated with poor prognosis and limited response to targeted therapies. Researchers found that MET amplification is frequently accompanied by co-amplifications of other oncogenes located on chromosome 7, such as BRAF, CDK6, and EGFR, in 54% of cases. These co-amplifications exhibit significant intra- and intertumoral heterogeneity. This complex heterogeneity may explain the diagnostic and therapeutic challenges, subclonal evolution, and the failure of targeted therapies in MET-amplified GCs.

Clinical · Molecular biology

Serum-based BRAF V600E detection improves early diagnosis of papillary thyroid carcinoma: A prospective diagnostic accuracy study compared with ultrasound-guided cytology

Li Q, Lu Y, Li X, et al.

Medicine

This prospective study evaluated the clinical value of serum-based BRAF V600E mutation detection, alone and in combination with ultrasound-guided fine-needle aspiration cytology (US-FNAC), for the preoperative diagnosis of papillary thyroid carcinoma (PTC). The study included 145 patients with small thyroid nodules. Results indicated that serum BRAF V600E detection, while comparable to US-FNAC in overall performance, showed significantly higher sensitivity for papillary thyroid microcarcinoma (micro-PTC). The integration of both methods substantially improved overall diagnostic performance, suggesting a complementary approach for earlier diagnosis and better risk stratification.

Clinical · Molecular biology

[Tuberous sclerosis complex-associated multifocal micronodular pneumocyte hyperplasia: a clinicopathological features and TSC1/TSC2 gene mutation analysis of eight cases]

Zhang PY, Wu CY, Wu W, et al.

Zhonghua bing li xue za zhi = Chinese journal of pathology

This retrospective study investigated eight cases of multifocal micronodular pneumocyte hyperplasia (MMPH) associated with tuberous sclerosis complex (TSC), a rare benign pulmonary lesion. Patients typically presented with multiple ground-glass nodules in the lungs on CT scans and various clinical manifestations of TSC. A significant diagnostic challenge was highlighted, as intraoperative frozen sections were often misdiagnosed as early-stage lung adenocarcinoma. Next-generation sequencing revealed TSC1 or TSC2 gene mutations in most patients, confirming the association with TSC. All followed-up patients showed a favorable overall survival.

Clinical · Molecular biology

Lung adenocarcinoma with malignant serous effusions: A comprehensive clinicopathologic, molecular, and outcome analysis

Ma W, Li J, Ould Ismail AA, et al.

Cancer cytopathology

This retrospective study analyzed 120 cases of lung adenocarcinoma (LUAD) with malignant serous effusions (MSE) to characterize their clinicopathologic, molecular, and prognostic features. Pleural effusions were most common, but pericardial involvement was associated with the shortest overall survival. Molecular profiling revealed TP53 mutations and actionable alterations in genes such as EGFR, KRAS, BRAF, ALK, and ROS1. NKX2-1 (TTF-1) negativity and the absence of actionable alterations were independent adverse prognostic factors, with dual NKX2-1/CD274 (PD-L1) negativity defining the poorest prognosis subgroup. Immunotherapy-based regimens and tyrosine kinase inhibitors showed varying survival benefits.

Clinical · Molecular biology · Bioinfo & AI

Functional precision oncology platform of BRAFV600E-mutated colorectal cancer organoids predicts therapy response and reveals RNF43-mediated immunogenicity

Mo S, Luo W, Yang J, et al.

Drug resistance updates

This study developed a functional precision oncology platform using patient-derived organoids (PDOs) and xenografts (PDOXs) from BRAFV600E-mutant colorectal cancer (CRC). The platform faithfully recapitulated tumor heterogeneity and drug responses. Researchers discovered that RNF43 mutations predict enhanced sensitivity to the encorafenib-cetuximab combination and increase tumor immunogenicity. These findings provide a mechanistic rationale for combining targeted therapies with immunotherapy in this aggressive CRC subtype.

Molecular biology

Utility of Urinary Extracellular Vesicles for Colorectal Cancer: Comparison of DNA Quality and MRD Detection

Kanaka S, Yamada T, Asai F, et al.

Cancer science

This study investigated the utility of urinary extracellular vesicles (EVs) as a liquid biopsy source for colorectal cancer (CRC). Urinary EVs demonstrated superior purity and DNA quality compared to plasma and urinary cell-free samples. Detecting RAS/BRAF mutations in urinary EV-DNA after curative surgery allowed for minimal residual disease (MRD) identification. MRD positivity was strongly associated with an increased risk of recurrence and inferior overall survival. These findings suggest that urinary EV-DNA is a promising tool for postoperative monitoring and risk stratification in CRC patients.